Bio

John Honts is a Senior Managing Director in the firm’s healthcare group, with a particular focus on the biopharma sector. Mr. Honts was involved in advising Takeda on its pending acquisition of Shire, Aetna on its pending sale to CVS, Teva on capital structure alternatives, AstraZeneca on its defense from Pfizer, Sanofi on its acquisition of Genzyme, Aptalis on its sale to Forest, Sanofi on its purchase Merck’s stake in Merial, Wyeth on its sale to Pfizer, CVS on its acquisition of Caremark, and Tyco on its restructuring which included the creation of Covidien. Mr. Honts was previously in investment banking at Merrill Lynch based in New York and London. Mr. Honts received a B.A. in finance / honors business from the University of Texas and an M.B.A. from the Stanford Graduate School of Business.